HPV VLP as adjunct therapy for recurrent respiratory papillomatosis.
Phase 1
- Conditions
- Patients with persistent or recurrent respiratory papillomatosis.Respiratory - Other respiratory disorders / diseases
- Registration Number
- ACTRN12607000016437
- Lead Sponsor
- Centre for Immunology and Cancer Research, University of Queensland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Otherwise healthy patients. Recurrent respiratory papillomatosis confirmed on laryngoscopy and by biopsy, with written case notes documenting the course of disease over the last year. Disease sufficiently severe to have required at least 3 documented excisional /ablative treatments over the 12 months prior to admission to the study. Consent from the parents after discussion with the treating paediatrician, and the third party specialist paediatrician.
Exclusion Criteria
Patients have hypersensitivity to any component of the vaccine or patients currently (or within three months prior to enrolment) taking systemic immunosuppressive or immunodulative medication wart therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method